This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Randomized, Double-Blind Comparison of Venlafaxine and Fluoxetine in Outpatients With Major Depression

Jorge Costa e Silva

Published: July 15, 1998

Article Abstract

Background: This was an 8-week, multicenter,randomized, double-blind, parallel-group study of the efficacyand tolerability of venlafaxine and fluoxetine.

Method: Outpatients with DSM-III-R majordepression, a minimum score of 20 on the 21item Hamilton RatingScale for Depression (HAM-D), and depressive symptoms for atleast 1 month were eligible. Patients were randomly assigned totreatment with venlafaxine, 37.5 mg twice daily, or fluoxetine,20 mg once daily. The dose could be increased to venlafaxine, 75mg twice daily, or fluoxetine, 20 mg twice daily, after 3 weeksfor a poor response. The primary efficacy variables were thefinal on-therapy scores on the HAM-D, Montgomery-AsbergDepression Rating Scale (MADRS), and Clinical Global ImpressionsSeverity of Illness (CGI-S) and Improvement (CGII) scales.

Results: Three hundred eighty-two patients wererandomly assigned to therapy and included in the intent-to-treatanalysis. Both venlafaxine and fluoxetine produced significantreductions from baseline to day 56 in mean HAM-D, MADRS, andCGI-S scores, but no significant differences were noted betweengroups. Among patients who increased their dose at 3 weeks,significantly (p < .05) more patients taking venlafaxine thantaking fluoxetine had a CGI-I score of 1 (very much improved) atthe final evaluation. The most frequent adverse events werenausea, headache, and dizziness with venlafaxine and nausea,headache, and insomnia with fluoxetine.

Conclusion: These results support the efficacyand tolerability of venlafaxine in comparison with fluoxetine fortreating outpatients with major depression.

Volume: 59

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...